We are live on ! Find out more
Ruffer

Ruffer Portfolio holdings

AUM $1.98B Turnover 35.71%
1-Year Est. Return 11.67%
 

Ruffer is an independent investment manager owned and run by its partners, with a single global strategy aimed at not losing money over any rolling 12-month period. Jonathan Ruffer, who began as a stockbroker and then became a barrister, started it in 1994 with Robert Shirley, 14th Earl Ferrers, and Jane Tufnell, and it became Ruffer LLP in 2004. The firm starts by weighing the risks it sees in markets and picking assets that should protect the portfolio if they come true, then takes on growth mainly through global stocks. It runs a stock-market-listed investment company, and its clients include pension plans, charities and family offices.

This Fund
S&P 500
This Quarter Est. Return
-8.55%
1 Year Est. Return
+11.67%
3 Year Est. Return
+123.28%
5 Year Est. Return
+179.62%
10 Year Est. Return
+587.82%
AUM
$3.16B
AUM Growth
-$410M
Cap. Flow
-$33.1M
Cap. Flow %
-1.05%
Top 10 Hldgs %
64.23%
Holding
98
New
9
Increased
25
Reduced
29
Closed
8
Avg Time Held
2.3 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
2 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$115M
2
CI icon
Cigna
CI
+$76.9M
3
WPM icon
Wheaton Precious Metals
WPM
+$42.8M
4
CAR icon
Avis
CAR
+$40.3M
5
KGC icon
Kinross Gold
KGC
+$36.4M

Sector Composition

Rank Sector Weight
1 Healthcare 31.32%
2 Materials 22.81%
3 Financials 15.4%
4 Consumer Staples 10.93%
5 Energy 10%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CI icon
1
Cigna
CI
$78.3B
$381M 12.07%
1,891,168
+353,754
+23% +$76.9M
2018 Q3
12 quarters
ABEV icon
2
Ambev
ABEV
$42.5B
$306M 9.68%
110,784,545
+591,395
+0.5% +$1.87M
2020 Q4
3 quarters
BMY icon
3
Bristol-Myers Squibb
BMY
$130B
$234M 7.4%
3,949,095
-300,178
-7% -$19.8M
2019 Q2
9 quarters
KGC icon
4
Kinross Gold
KGC
$24.5B
$219M 6.93%
41,391,135
+6,080,481
+17% +$36.4M
2013 Q2
33 quarters
CNC icon
5
Centene
CNC
$35.3B
$214M 6.77%
3,408,459
-2,048,070
-38% -$137M
2019 Q3
8 quarters
WPM icon
6
Wheaton Precious Metals
WPM
$59.7B
$160M 5.06%
4,342,517
+980,707
+29% +$42.8M
2015 Q3
24 quarters
EXE icon
7
Expand Energy Corp
EXE
$20.4B
$156M 4.94%
2,529,579
-65,365
-3% -$3.66M
2021 Q1
2 quarters
AXP icon
8
American Express
AXP
$215B
$140M 4.43%
807,942
-255,265
-24% -$42.7M
2020 Q2
5 quarters
AZN icon
9
AstraZeneca
AZN
$286B
$117M 3.7%
+985,898
New +$115M
2021 Q3
0 quarters
FHI icon
10
Federated Hermes
FHI
$4.71B
$103M 3.25%
3,160,276
-35,526
-1% -$1.16M
2021 Q2
1 quarter
EHTH icon
11
eHealth
EHTH
$13.4M
$88.9M 2.81%
2,156,575
+282,785
+15% +$13.2M
2019 Q4
7 quarters
CTRA icon
12
DELISTED
Coterra Energy
CTRA
$80.2M 2.54%
3,621,149
+157,930
+5% +$2.71M
2020 Q3
4 quarters
GM icon
13
General Motors
GM
$72.5B
$78M 2.47%
1,474,995
+137,067
+10% +$7.29M
2018 Q2
13 quarters
AU icon
14
AngloGold Ashanti
AU
$43.7B
$68.5M 2.17%
4,245,122
+172,100
+4% +$2.98M
2015 Q2
25 quarters
NOC icon
15
Northrop Grumman
NOC
$78.2B
$66.9M 2.12%
186,234
+9,319
+5% +$3.37M
2021 Q2
1 quarter
XOM icon
16
ExxonMobil
XOM
$696B
$66.2M 2.1%
1,092,229
+124,433
+13% +$7.09M
2013 Q2
33 quarters
SCHW icon
17
Charles Schwab
SCHW
$160B
$57.2M 1.81%
772,192
-10,738
-1% -$767K
2020 Q2
5 quarters
CAR icon
18
Avis
CAR
$4.43B
$55.5M 1.76%
+457,636
New +$40.3M
2021 Q3
0 quarters
GFI icon
19
Gold Fields
GFI
$31.6B
$55.1M 1.74%
6,767,015
+803,878
+13% +$7.19M
2013 Q2
33 quarters
CGAU icon
20
Centerra Gold
CGAU
$3.92B
$42.5M 1.34%
6,079,550
+45,000
+0.7% +$333K
2021 Q2
1 quarter
JPM icon
21
JPMorgan Chase
JPM
$919B
$38.5M 1.22%
231,431
-10,246
-4% -$1.61M
2013 Q2
33 quarters
BRK.B icon
22
Berkshire Hathaway Class B
BRK.B
$1.26T
$36.1M 1.14%
131,556
-12,304
-9% -$3.46M
2020 Q2
5 quarters
NEM icon
23
Newmont
NEM
$118B
$36M 1.14%
676,154
+98,292
+17% +$5.8M
2015 Q4
23 quarters
B icon
24
Barrick Mining
B
$61.2B
$34M 1.07%
1,900,597
+394,321
+26% +$7.92M
2013 Q4
31 quarters
COTY icon
25
Coty
COTY
$3.56B
$29.6M 0.94%
3,637,910
+115,585
+3% +$989K
2020 Q2
5 quarters

Similar funds

Ruffer's Q3 2021 Portfolio in Review

As of Q3 2021, Ruffer held 98 positions worth $3.16B, down 11% from $3.57B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Ruffer's Q3 2021 filing shows 9 new, 25 increased, 29 reduced and 8 closed positions. Its largest new stake was AstraZeneca: 985,898 shares worth $117M. The largest sale was Alexion Pharmaceuticals, an estimated $183M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 35% a quarter earlier, followed by Materials and Financials.

  • Ruffer's largest Q3 2021 buy was AstraZeneca: 985,898 shares worth $117M.
  • Ruffer added most to Cigna in Q3 2021, an estimated $76.9M increase.
  • Ruffer's biggest Q3 2021 reduction was Centene, cutting an estimated $137M.
  • Ruffer fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $183M.
  • Ruffer's ten largest holdings make up 64% of its $3.16B portfolio in Q3 2021.
  • Ruffer opened 9 new positions and closed 8 in Q3 2021.
  • Ruffer's portfolio value fell 11% quarter-over-quarter to $3.16B.

Based on Ruffer's 13F filing for Q3 2021, filed 10 Nov 2021.